Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.

Journal of virology - 26 Jan 2022

Khatun Mousumi, Kumar Krishna, Baidya Ayana, Mondal Rajiv Kumar, Baszczyňski Ondřej, Kalčic Filip, Banerjee Soma, Dhali Gopal Krishna, Das Kausik, Chowdhury Abhijit, Janeba Zlatko, Chakrabarti Saikat, Datta Simanti

Abstract excerpt

Nucleos(t)ide analogues entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are recommended as first-line monotherapies for chronic hepatitis B (CHB). Multiple HBV genotypes/subgenotypes have been described, but their impact on treatment response remains largely elusive. We investigated the effectiveness of ETV/TDF on HBV/D-subgenotypes, D1/D2/D3/D5, studied the structural/functional differences in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to Guanine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Organophosphonates

Share to Prodrugs

Share to Reverse Transcriptase Inhibitors

Share to RNA-Directed DNA Polymerase

Share to Tenofovir

Source

Open in PubMed Open full text

Identifiers

PMID: 34730399
DOI: 10.1128/JVI.01800-21
PMCID: PMC8791253

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.PMID 34730399Read ↗

Distinctiveness in virological features and pathogenic potentials of subgenotypes D1, D2, D3 and D5 of Hepatitis B virus.Semantic proximity Read ↗

Molecular characterization of hepatitis B virus reveals circulation of multiple subgenotypes of genotype D with clinically important mutations in central India.Semantic proximity Read ↗

Epidemiology of HBV subgenotypes D.Semantic proximity Read ↗

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Semantic proximity Read ↗

HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D.Semantic proximity Read ↗

Current developments in nucleoside/nucleotide analogues for hepatitis B.Semantic proximity Read ↗

Classification and sequencing of hepatitis D virus from a large cohort of chronically infected individuals paired with co-infecting hepatitis B virus sequencing: a genomic characterisation study.Semantic proximity Read ↗

Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D.Semantic proximity Read ↗

Drug resistance mutations of hepatitis B virus (HBV) influence the yield of the virions of the human hepatitis delta virus (HDV) and their infectivity.Semantic proximity Read ↗

A rare HBV subgenotype D4 with unique genomic signatures identified in north-eastern India--an emerging clinical challenge?Semantic proximity Read ↗

Characterization of hepatitis virus B isolated from a multi-drug refractory patient.Semantic proximity Read ↗

New HBV subgenotype D9, a novel D/C recombinant, identified in patients with chronic HBeAg-negative infection in Eastern India.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.